Pipeline

Programs

Athos Therapeutics is currently advancing two preclinical programs for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases and cancer.

Disease/Indication

Compound

Discovery

Preclinical

Phase 1

Primary Programs

2022

IBD

(Moderate-to-severe, anti-TNFA refractory & colonic disease)

ATH-63 (Gene A)

IBD

(Moderate, anti-TNFA naive colonic & ileal disease)

ATH-105 (Gene B)

Secondary Programs

2022

Oncology

ATH-73 (Gene A)

SLE

ATH-XX (Gene A)

SLE

ATH-XX (Gene X)